$AGIO
AGIOS PHARMACEUTICALS, INC.

2014 Q2 Form 10-Q Financial Statement

#000119312514300949 Filed on August 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q2
Revenue $8.411M $6.268M
YoY Change 34.19% -0.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.170M $1.840M
YoY Change 126.63% -5.64%
% of Gross Profit
Research & Development $22.58M $12.96M
YoY Change 74.22% 23.85%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K
YoY Change 0.0% 100.0%
% of Gross Profit
Operating Expenses $26.74M $14.79M
YoY Change 80.76% 19.2%
Operating Profit -$18.33M -$8.526M
YoY Change 114.99% 39.25%
Interest Expense $30.00K $10.00K
YoY Change 200.0% -50.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$18.30M -$8.521M
YoY Change 114.72% 39.67%
Income Tax $0.00 $99.00K
% Of Pretax Income
Net Earnings -$18.30M -$8.620M
YoY Change 112.25% 56.36%
Net Earnings / Revenue -217.52% -137.52%
Basic Earnings Per Share -$0.54
Diluted Earnings Per Share -$0.54 -$2.317M
COMMON SHARES
Basic Shares Outstanding 33.96M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $238.5M $99.30M
YoY Change 140.16%
Cash & Equivalents $108.2M $77.48M
Short-Term Investments $130.2M $21.80M
Other Short-Term Assets $6.600M $3.200M
YoY Change 106.25%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $245.2M $102.5M
YoY Change 139.11%
LONG-TERM ASSETS
Property, Plant & Equipment $3.210M $3.818M
YoY Change -15.92%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $22.60M
YoY Change
Other Assets $455.0K $1.624M
YoY Change -71.98%
Total Long-Term Assets $26.87M $8.719M
YoY Change 208.14%
TOTAL ASSETS
Total Short-Term Assets $245.2M $102.5M
Total Long-Term Assets $26.87M $8.719M
Total Assets $272.0M $111.3M
YoY Change 144.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.388M $3.038M
YoY Change 77.35%
Accrued Expenses $5.456M $3.586M
YoY Change 52.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $44.64M $36.98M
YoY Change 20.71%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.000K $45.40M
YoY Change -100.0%
Total Long-Term Liabilities $2.000K $45.40M
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $44.64M $36.98M
Total Long-Term Liabilities $2.000K $45.40M
Total Liabilities $44.64M $82.40M
YoY Change -45.83%
SHAREHOLDERS EQUITY
Retained Earnings -$144.0M -$89.89M
YoY Change 60.19%
Common Stock $344.5M $2.840M
YoY Change 12031.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $200.5M -$87.05M
YoY Change
Total Liabilities & Shareholders Equity $272.0M $111.3M
YoY Change 144.52%

Cashflow Statement

Concept 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$18.30M -$8.620M
YoY Change 112.25% 56.36%
Depreciation, Depletion And Amortization $400.0K $400.0K
YoY Change 0.0% 100.0%
Cash From Operating Activities -$1.100M -$15.80M
YoY Change -93.04% 50.48%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K -$700.0K
YoY Change -85.71% 133.33%
Acquisitions
YoY Change
Other Investing Activities -$18.50M $10.60M
YoY Change -274.53% -303.85%
Cash From Investing Activities -$18.60M $9.900M
YoY Change -287.88% -280.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 95.10M 100.0K
YoY Change 95000.0% 0.0%
NET CHANGE
Cash From Operating Activities -1.100M -15.80M
Cash From Investing Activities -18.60M 9.900M
Cash From Financing Activities 95.10M 100.0K
Net Change In Cash 75.40M -5.800M
YoY Change -1400.0% -63.52%
FREE CASH FLOW
Cash From Operating Activities -$1.100M -$15.80M
Capital Expenditures -$100.0K -$700.0K
Free Cash Flow -$1.000M -$15.10M
YoY Change -93.38% 48.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority
IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
3800000
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34458016 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77481000
CY2013Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34424415 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1720163 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34424415 shares
CY2014Q2 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
66 Securities
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.54
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3983561 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.77
CY2014Q2 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0 Securities
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3297987 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.43
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5456000
CY2014Q2 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
700000
CY2014Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
93000
CY2014Q2 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5388000
CY2014Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
620000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44638000
CY2014Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2371000
CY2014Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
200548000
CY2014Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
344490000
CY2014Q2 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
12000
CY2014Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143988000
CY2014Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33644000
CY2014Q2 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
145000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2014Q2 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
142000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
272030000
CY2014Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8000
CY2014Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
26697000
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Assets Current
AssetsCurrent
245163000
CY2014Q2 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
22631000
CY2014Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
152852000
CY2014Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3841000
CY2014Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
455000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
112303000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
108247000
CY2014Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
130233000
CY2014Q2 us-gaap Assets
Assets
272030000
CY2014Q2 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
76357000
CY2014Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
152864000
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2842000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
132591000
CY2014Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2014Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
57400000
CY2014Q2 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3210000
CY2014Q2 agio Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
36000
CY2014Q2 agio Available For Sale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
24000
CY2014Q2 agio Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event
PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent
22500000
CY2014Q2 agio One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program
OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram
25000000
CY2014Q2 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
2372000
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
10700000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
91297000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31202542 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31202542 shares
CY2013Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
33 Securities
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.14
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3846168 shares
CY2013Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0 Securities
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6586000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
140000
CY2013Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3678000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
320000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36930000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3642000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
131482000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244881000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
14000
CY2013Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-113444000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
25072000
CY2013Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
1462000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
220000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
123000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
201205000
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
32567000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
169747000
CY2013Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
27125000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
122320000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
571000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
95209000
CY2013Q4 us-gaap Assets
Assets
201205000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71560000
CY2013Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
476000
CY2013Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122334000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2502000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
76189000
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
31700000
CY2013Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3758000
CY2013Q4 agio Available For Sale Debt Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedGainAccumulatedInInvestments
20000
CY2013Q4 agio Available For Sale Debt Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleDebtSecuritiesGrossUnrealizedLossAccumulatedInInvestments
6000
CY2013Q4 agio Accrued Contracted Research And Development Costs Current
AccruedContractedResearchAndDevelopmentCostsCurrent
2484000
CY2013Q4 agio Unbilled Contracts Receivable From Related Party
UnbilledContractsReceivableFromRelatedParty
5000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9185 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M27D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3690669 shares
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-27803000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.27
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23452549 shares
us-gaap Revenues
Revenues
12500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15850000
us-gaap Contracts Revenue
ContractsRevenue
12536000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15559000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
23195000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19443000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15572000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2690000
us-gaap Net Income Loss
NetIncomeLoss
-15848000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
9000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
976000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1845000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3688000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
72000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-12536000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
us-gaap Share Based Compensation
ShareBasedCompensation
753000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13816000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-36000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
13915000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
266000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-271000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24420000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
72000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
289000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
38086000
us-gaap Depreciation
Depreciation
723000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
753000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
289000
us-gaap Operating Expenses
OperatingExpenses
28108000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3595000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
289000
dei Trading Symbol
TradingSymbol
AGIO
dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001439222
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0182 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8534 pure
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.75
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.45
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y7D
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32506739 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
32.76
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28111000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.64
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1072809 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M9D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M13D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
912783 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
327272 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
22633 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3997765 shares
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3636 pure
us-gaap Revenues
Revenues
16800000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30546000
us-gaap Contracts Revenue
ContractsRevenue
16822000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30544000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
126338000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30544000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
121200000
us-gaap Income Taxes Paid
IncomeTaxesPaid
5958000
us-gaap Investment Income Interest
InvestmentIncomeInterest
70000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30614000
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
791000
us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-476000
us-gaap Net Income Loss
NetIncomeLoss
-30544000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-305000
us-gaap Royalty Revenue
RoyaltyRevenue
0
us-gaap Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Amount
RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
124300000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1130000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7454000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
95734000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2702000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
34800000
us-gaap Share Based Compensation
ShareBasedCompensation
3886000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
36687000
us-gaap Increase Decrease In Other Deferred Liability
IncreaseDecreaseInOtherDeferredLiability
-55000
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-30936000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-5303000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1684000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
94698000
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39982000
agio Vesting Of Restricted Stock Value
VestingOfRestrictedStockValue
6000
agio Estimated Performance Period Of Agreement
EstimatedPerformancePeriodOfAgreement
P6Y
us-gaap Operating Expenses
OperatingExpenses
47436000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1036000
us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
95501000
us-gaap Depreciation
Depreciation
659000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3886000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
agio Number Of Vendors Selling Similar Competitive Products
NumberOfVendorsSellingSimilarCompetitiveProducts
0 Vendor
agio Number Of Licensed Programs Type Under Collaboration Agreements
NumberOfLicensedProgramsTypeUnderCollaborationAgreements
3 Licensed_Program
agio Period Considered For Agreement Termination Notice
PeriodConsideredForAgreementTerminationNotice
P30D
agio Number Of Development Candidates Nominated By Joint Research Committee
NumberOfDevelopmentCandidatesNominatedByJointResearchCommittee
2 Candidate
agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
4300000
agio Public Offering Costs Included In Accounts Payable
PublicOfferingCostsIncludedInAccountsPayable
13000
CY2013Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
19731564 shares
CY2010Q2 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2014-04
CY2010Q2 agio Discover Period Under Collaboration Agreement
DiscoverPeriodUnderCollaborationAgreement
P2Y
CY2010Q2 agio Agreement Amended Period
AgreementAmendedPeriod
2011-10
CY2011Q4 agio Initial Agreement Period
InitialAgreementPeriod
P3Y
CY2011Q4 agio Extended Agreement Period
ExtendedAgreementPeriod
P4Y
CY2011Q4 agio Receipt Due To Agreement Amendment
ReceiptDueToAgreementAmendment
20000000
CY2014Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
5958000
CY2014Q1 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
1500000
CY2013Q4 agio Initial Agreement Period
InitialAgreementPeriod
P4Y
CY2013Q4 agio Date Of Extension Of Discovery Phase
DateOfExtensionOfDiscoveryPhase
2016-04
CY2013Q4 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2015-04
CY2013Q4 agio Extended Agreement Period
ExtendedAgreementPeriod
P5Y
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M5D
CY2013 agio Initial Agreement Period
InitialAgreementPeriod
P4Y
CY2013 agio Research Collaborative Arrangement Expiration Period
ResearchCollaborativeArrangementExpirationPeriod
2015-04
CY2013 agio Extended Agreement Period
ExtendedAgreementPeriod
P5Y
CY2013 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
500000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0100 pure
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9185 pure
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M27D
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3722963 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.88
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.80
CY2013Q2 us-gaap Revenues
Revenues
6300000
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8623000
CY2013Q2 us-gaap Contracts Revenue
ContractsRevenue
6268000
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8521000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10418000
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5000
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8526000
CY2013Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-8620000
CY2013Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1836000
CY2013Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2013Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2013Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12958000
CY2013Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2013Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
99000
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
329000
CY2013Q2 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
99000
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
14794000
CY2013Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
1798000
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
99000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0181 pure
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8800 pure
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M21D
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33602472 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
27.84
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2014Q2 us-gaap Revenues
Revenues
8400000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18317000
CY2014Q2 us-gaap Contracts Revenue
ContractsRevenue
8411000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18296000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18296000
CY2014Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
34000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18330000
CY2014Q2 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-18296000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4165000
CY2014Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10700000
CY2014Q2 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2014Q2 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22576000
CY2014Q2 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2381000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
26741000
CY2014Q2 agio Revenue Recognized On Extended Agreement
RevenueRecognizedOnExtendedAgreement
2100000

Files In Submission

Name View Source Status
0001193125-14-300949-index-headers.html Edgar Link pending
0001193125-14-300949-index.html Edgar Link pending
0001193125-14-300949.txt Edgar Link pending
0001193125-14-300949-xbrl.zip Edgar Link pending
agio-20140630.xml Edgar Link completed
agio-20140630.xsd Edgar Link pending
agio-20140630_cal.xml Edgar Link unprocessable
agio-20140630_def.xml Edgar Link unprocessable
agio-20140630_lab.xml Edgar Link unprocessable
agio-20140630_pre.xml Edgar Link unprocessable
d760215d10q.htm Edgar Link pending
d760215dex311.htm Edgar Link pending
d760215dex312.htm Edgar Link pending
d760215dex321.htm Edgar Link pending
d760215dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending